Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6826)
All Articles published online
|
Publishing Process of This Article
|
Jul 21, 2014 (publication date) through Jul 12, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Liu Y, Wei R, Hong TP. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(27): 9090-9097 [PMID: 25083081 DOI: 10.3748/wjg.v20.i27.9090] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i27/9090.htm |
| Number | Citing Articles |
| 1 |
Rodrigo Carlessi, Natalia E. Lemos, Ana L. Dias, Leticia A. Brondani, Jarbas R. Oliveira, Andrea C. Bauer, Cristiane B. Leitão, Daisy Crispim. Exendin‐4 attenuates brain death–induced liver damage in the rat. Liver Transplantation 2015; 21(11): 1410 doi: 10.1002/lt.24317
|
| 2 |
A. Dutour, I. Abdesselam, P. Ancel, F. Kober, G. Mrad, P. Darmon, O. Ronsin, V. Pradel, N. Lesavre, J. C. Martin, A. Jacquier, Y. Lefur, M. Bernard, B. Gaborit. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes, Obesity and Metabolism 2016; 18(9): 882 doi: 10.1111/dom.12680
|
| 3 |
Hsin-Hsien Yu, Hao-Chen Wang, Mao-Chih Hsieh, Ming-Che Lee, Bor-Chyuan Su, Yan-Shen Shan, Si Qin. Exendin‐4 Attenuates Hepatic Steatosis by Promoting the Autophagy‐Lysosomal Pathway. BioMed Research International 2022; 2022(1) doi: 10.1155/2022/4246086
|
| 4 |
Junzi Wu, Gareth R. Williams, Christopher Branford-White, Heyu Li, Yan Li, Li-Min Zhu. Liraglutide-loaded poly(lactic-co-glycolic acid) microspheres: Preparation and in vivo evaluation. European Journal of Pharmaceutical Sciences 2016; 92: 28 doi: 10.1016/j.ejps.2016.06.018
|
| 5 |
J.-M. Petit, B. Vergès. GLP-1 receptor agonists in NAFLD. Diabetes & Metabolism 2017; 43: 2S28 doi: 10.1016/S1262-3636(17)30070-8
|
| 6 |
Tao Zhang, Yingli Nie, Jiliang Wang. The emerging significance of mitochondrial targeted strategies in NAFLD treatment. Life Sciences 2023; 329: 121943 doi: 10.1016/j.lfs.2023.121943
|
| 7 |
Nicholas W. S. Chew, Cheng Han Ng, Emily Truong, Mazen Noureddin, Kris V. Kowdley. Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. Seminars in Liver Disease 2022; 42(03): 379 doi: 10.1055/a-1877-9656
|
| 8 |
Na Ao, Jing Yang, Xiaochen Wang, Jian Du. Glucagon‐like peptide‐1 preserves non‐alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress‐associated pathway. Hepatology Research 2016; 46(4): 343 doi: 10.1111/hepr.12551
|
| 9 |
Tian Shen, Bilin Xu, Tao Lei, Lin Chen, Cuiping Zhang, Zhenhua Ni. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.6554
|
| 10 |
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin, Jinbo Yang. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy 2022; 7(1) doi: 10.1038/s41392-022-01119-3
|
| 11 |
Ali A Rizvi, Angelo Maria Patti, Rosaria Vincenza Giglio, Dragana Nikolic, Antonella Amato, Noor Al-Busaidi, Khalid Al-Rasadi, Maurizio Soresi, Maciej Banach, Giuseppe Montalto, Manfredi Rizzo. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. Expert Opinion on Biological Therapy 2015; 15(10): 1391 doi: 10.1517/14712598.2015.1067299
|
| 12 |
Khalidur Rahman, Yunshan Liu, Pradeep Kumar, Tekla Smith, Natalie E Thorn, Alton B Farris, Frank A Anania. C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis. Laboratory Investigation 2016; 96(8): 895 doi: 10.1038/labinvest.2016.61
|
| 13 |
Saurabh Srivastava, Amit Gupta, Deepak Sharma, Anuj Maheshwari, Nadima Shaikeh, Rakesh Sahay, Noel C Barengo. Effect of glucagon on lipid metabolism. Journal of Diabetology 2023; 14(Supplement 1): S25 doi: 10.4103/jod.jod_99_23
|
| 14 |
Haoran Jiang, Linquan Zang. GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD. Current Pharmaceutical Design 2024; 30(2): 100 doi: 10.2174/0113816128283153231226103218
|
| 15 |
Emerging Therapies and Therapeutic Targets for Composite Liver Disease: NASH. Current Topics in Medicinal Chemistry 2023; 23(21): 2027 doi: 10.2174/1568026623666230714113808
|
| 16 |
Zhiyu Li, Chao Cui, Liang Xu, Mingfeng Ding, Yinghui Wang. Metformin suppresses metabolic dysfunction-associated fatty liver disease by ferroptosis and apoptosis via activation of oxidative stress. Free Radical Research 2024; 58(11): 686 doi: 10.1080/10715762.2024.2417279
|
| 17 |
Eunüs S. Ali, Jin Hua, Claire H. Wilson, George A. Tallis, Fiona H. Zhou, Grigori Y. Rychkov, Greg J. Barritt. The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca 2+ signalling in steatotic hepatocytes. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2016; 1863(9): 2135 doi: 10.1016/j.bbamcr.2016.05.006
|
| 18 |
Lilian Calderón-Garcidueñas, Maricela Franco-Lira, Amedeo D'Angiulli, Joel Rodríguez-Díaz, Eleonore Blaurock-Busch, Yvette Busch, Chih-kai Chao, Charles Thompson, Partha S. Mukherjee, Ricardo Torres-Jardón, George Perry. Mexico City normal weight children exposed to high concentrations of ambient PM2.5 show high blood leptin and endothelin-1, vitamin D deficiency, and food reward hormone dysregulation versus low pollution controls. Relevance for obesity and Alzheimer disease. Environmental Research 2015; 140: 579 doi: 10.1016/j.envres.2015.05.012
|
| 19 |
Mark M Smits, Daniel H van Raalte, Lennart Tonneijck, Marcel H A Muskiet, Mark H H Kramer, Djuna L Cahen. GLP-1 based therapies: clinical implications for gastroenterologists. Gut 2016; 65(4): 702 doi: 10.1136/gutjnl-2015-310572
|
| 20 |
Masoud Nouri-Vaskeh, Neda Khalili, Amirreza Khalaji, Pouya Behnam, Leila Alizadeh, Sara Ebrahimi, Neda Gilani, Mehdi Mohammadi, Seyed Alisalar Madinehzadeh, Mohammad Zarei. Circulating glucagon-like peptide-1 level in patients with liver cirrhosis. Archives of Physiology and Biochemistry 2023; 129(2): 373 doi: 10.1080/13813455.2020.1828479
|
| 21 |
Xiaotong Kong, Jianjian Wang, Yuze Cao, Xiaoyu Lu, Huixue Zhang, XiaoMing Zhang, Chunrui Bo, Ming Bai, Shuang Li, Yang Jiao, Lihua Wang. Construction of miRNA-regulated drug-pathway network to screen drug repurposing candidates for multiple sclerosis. Medicine 2022; 101(11) doi: 10.1097/MD.0000000000029107
|
| 22 |
Ides M. Colin, Henri Colin, Ines Dufour, Charles‐Edouard Gielen, Marie‐Christine Many, Jean Saey, Bernard Knoops, Anne‐Catherine Gérard. Extrapancreatic effects of incretin hormones: evidence for weight‐independent changes in morphological aspects and oxidative status in insulin‐sensitive organs of the obese nondiabetic Zucker rat (ZFR). Physiological Reports 2016; 4(15) doi: 10.14814/phy2.12886
|
| 23 |
Tomasz Charytoniuk, Krzysztof Drygalski, Karolina Konstantynowicz-Nowicka, Klaudia Berk, Adrian Chabowski. Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials. Nutrition 2017; 34: 108 doi: 10.1016/j.nut.2016.09.001
|
| 24 |
Amir Zarrinpar, Amandine Chaix, Satchidananda Panda. Daily Eating Patterns and Their Impact on Health and Disease. Trends in Endocrinology & Metabolism 2016; 27(2): 69 doi: 10.1016/j.tem.2015.11.007
|
| 25 |
Eun Ran Kim, Jeong Su Park, Jin Hee Kim, Ji Young Oh, In Jeong Oh, Da Hyun Choi, Yu seol Lee, I. Seul Park, SeungWon Kim, Da Hyun Lee, Jae Hee Cheon, Jin‐Woo Bae, Minyoung Lee, Jin Won Cho, In Bok An, Eun Joo Nam, Sang‐In Yang, Myung‐Shik Lee, Soo Han Bae, Yong‐ho Lee. A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome. Hepatology 2022; 75(6): 1523 doi: 10.1002/hep.32235
|
| 26 |
Qin Pan, Jian-Gao Fan, Yusuf Yilmaz. Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2023; 27(2): 317 doi: 10.1016/j.cld.2023.01.013
|